These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 17490557)

  • 1. [Experimental advance of targeted medicines for chronic myeloid leukemia--review].
    Yang DG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):211-4. PubMed ID: 17490557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tyrosine kinase inhibitors for the treatment of CML].
    Heim D
    Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib mesylate (STI 571)--a new oral target therapy for chronic myelogenous leukemia (CML).
    Chrobák L; Voglová J
    Acta Medica (Hradec Kralove); 2003; 46(3):85-9. PubMed ID: 14677715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
    Usui N
    Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
    Mahon FX; Réa D; Guilhot J; Guilhot F; Huguet F; Nicolini F; Legros L; Charbonnier A; Guerci A; Varet B; Etienne G; Reiffers J; Rousselot P;
    Lancet Oncol; 2010 Nov; 11(11):1029-35. PubMed ID: 20965785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uptake of imatinib-loaded polyelectrolyte complexes by BCR-ABL(+) cells: a long-acting drug-delivery strategy for targeting oncoprotein activity.
    Palamà IE; Coluccia AM; Gigli G
    Nanomedicine (Lond); 2014 Jul; 9(14):2087-98. PubMed ID: 24364873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific targeted therapy of chronic myelogenous leukemia with imatinib.
    Deininger MW; Druker BJ
    Pharmacol Rev; 2003 Sep; 55(3):401-23. PubMed ID: 12869662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase].
    Voglová J; Maisnar V; Beránek M; Chrobák L
    Vnitr Lek; 2006 Sep; 52(9):819-22. PubMed ID: 17091608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [TKI therapy for CML].
    Ohnishi K
    Rinsho Ketsueki; 2011 Jul; 52(7):452-9. PubMed ID: 21821976
    [No Abstract]   [Full Text] [Related]  

  • 13. Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?
    Jabbour E; Cortes J; Kantarjian H
    Oncology (Williston Park); 2007 May; 21(6):653-62; discussion 663-4, 667-8. PubMed ID: 17564324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.
    Kalmanti L; Saussele S; Lauseker M; Müller MC; Dietz CT; Heinrich L; Hanfstein B; Proetel U; Fabarius A; Krause SW; Rinaldetti S; Dengler J; Falge C; Oppliger-Leibundgut E; Burchert A; Neubauer A; Kanz L; Stegelmann F; Pfreundschuh M; Spiekermann K; Scheid C; Pfirrmann M; Hochhaus A; Hasford J; Hehlmann R
    Leukemia; 2015 May; 29(5):1123-32. PubMed ID: 25676422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of LMO2 protein expression on survival in chronic myeloid leukemia patients treated with imatinib mesylate.
    Sonmez M; Akagun T; Cobanoglu U; Topbas M; Erkut N; Yilmaz M; Ovali E; Omay SB
    Hematology; 2009 Aug; 14(4):220-3. PubMed ID: 19635185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
    N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing.
    Faber E; Nausová J; Jarosová M; Egorin MJ; Holzerová M; Rozmanová S; Maresová I; Divoký V; Indrák K
    Leuk Lymphoma; 2006 Jun; 47(6):1082-90. PubMed ID: 16840200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New drug targets genetic malfunction in chronic myeloid leukemia.
    Am J Health Syst Pharm; 2001 Jul; 58(14):1282. PubMed ID: 11471471
    [No Abstract]   [Full Text] [Related]  

  • 20. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.